FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for the treatment of patients with celiac disease with cholelithiasis of the 1st stage in the setting of an anomaly of the gallbladder. Patients with celiac disease with cholelithiasis of the 1st stage with an anomaly of the gallbladder in the setting of pathogenetic nutrition are subjected to influencing muscular-fascial regions of the back, thoracic region of the spine Th7-Th9, duodenum (12 fw), sphincter of Oddi, common bile duct, gall bladder, right dome of the medullary diaphragm, ligamentous apparatus of the liver.
EFFECT: method widens the range of therapeutic agents.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED AGENT CONTAINING UDCA AND HYMECROMONE (EMBODIMENTS) | 2017 |
|
RU2689798C1 |
| COMBINED AGENT CONTAINING UDCA, HYMECROMONE AND SILYMARIN (VERSIONS) | 2017 |
|
RU2738444C2 |
| METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
| METHOD OF CONSERVATIVE TREATMENT OF LITHIC STAGE OF CHOLELITHIASIS | 2012 |
|
RU2490017C1 |
| METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
| METHOD OF DETEMINING DYSKINESIS OF BILE BLADDER AND ODDI'S SPHINCTER | 2007 |
|
RU2369333C2 |
| METHOD FOR EARLY DIAGNOSTICS OF CHOLELITHIASIS | 2004 |
|
RU2254809C1 |
| NEW COMPOSITIONS | 2021 |
|
RU2771565C1 |
| METHOD OF PROPHYLAXIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHOLELITHIASIS AFTER LAPAROSCOPIC CHOLECYSTECTOMY | 2017 |
|
RU2657838C1 |
| METHOD FOR SETTING DIFFERENTIAL DIAGNOSIS OF ODDI SPHINCTER DYSFUNCTION | 2004 |
|
RU2245102C1 |
